CD8A and rectal cancer: A high density of CD8+ cell (OR 2.69, 95% CI 1.45–4.98, p = 0.002) in biopsy samples has been linked with good CRT response, which was considered a good biomarker for predicting outcome after neoadjuvant therapy for rectal cancer [35].